Washington-based pharmaceutical company founded by Dr. Andrew Chadeayne, focused on psychedelic drug discovery, development and intellectual property. As one of the earliest drug-discovery firms in the space, it has synthesized and characterized a large library of novel psychedelic molecules and filed over 100 patent applications, with research collaborations at academic institutions.
CaaMTech News 5 articles
- CaaMTech Creates Two New Prodrugs of 4-HO-DiPT
- CaaMTech Publishes Fundamental Research on Aeruginascin Derivatives
- CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
- CaaMTech: Utilizing the Entourage Effect to Transform Psychedelic Medicine
- CaaMTech Collaborates With the Leibniz Institute for Natural Product Research to Investigate Psychedelic Mushrooms